Skip to main content
main-content

01.12.2017 | Review | Ausgabe 1/2017 Open Access

Orphanet Journal of Rare Diseases 1/2017

Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy – a literature review

Zeitschrift:
Orphanet Journal of Rare Diseases > Ausgabe 1/2017
Autoren:
Ingrid E. C. Verhaart, Agata Robertson, Ian J. Wilson, Annemieke Aartsma-Rus, Shona Cameron, Cynthia C. Jones, Suzanne F. Cook, Hanns Lochmüller
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​s13023-017-0671-8) contains supplementary material, which is available to authorized users.
Abbreviations
ALS
Amyotrophic lateral sclerosis
PMA
Progressive muscular atrophy
SMA
Spinal muscular atrophy
SMN
Survival motor neuron

Background

Spinal muscular atrophy (SMA) is characterised by degeneration of the alpha motor neurons of the spinal cord anterior horn cells, leading to progressive proximal muscle weakness and atrophy and, in the most severe types, paralysis.
The clinical phenotype of SMA is heterogeneous, ranging from a severe to a mild phenotype. It is generally divided into three main subtypes: type I (also called Werdnig Hoffmann disease), type II and, type III (also called Kugelberg Welander disease). However, these phenotypes are seen more as a continuum rather than as distinct subtypes and sometimes further subtypes at both ends of the spectrum are observed. SMA type 0 is a very severe form with onset in utero, reduced or absent movements, contractures, and requirement for mechanical ventilation support at birth and death before six months of age, while SMA type IV is a mild late (adult) onset form that has a normal life expectancy [ 1, 2]. An overview of the different subtypes is given in Table 1.
Table 1
Clinical classification of spinal muscular atrophy
SMA type
OMIM number
Age of onset
Highest achieved motor function
Natural age of death
0
-
Prenatal/ Foetal
Nil
<6 months
I
253300
<6 months
Sit with support only
<2 years
II
253550
6–18 months
Sit independently
>2 years
III
253400
>18 months
Stand and walk
Adulthood
IV
271150
Adult (2nd or 3rd decade)
Walk during adulthood
Adult
OMIM Online Mendelian Inheritance in Man
SMA is inherited in an autosomal recessive manner. In most cases it is caused by mutations in the survival motor neuron 1 ( SMN1, SMN T , telomeric) gene, located on chromosome 5q13.2 [ 3]. In rare cases (~4%) SMA is caused by mutation in another gene (non-5q SMA). The majority of the patients (92%) have a homozygous deletion of SMN1. In the remaining patients small mutations that abolish the production of the SMN protein are found, mostly in a combination with an SMN1 deletion (~4%) [ 4, 5]. A centromeric homologue of the gene, SMN2, (previously also called SMN C or C BCD541) is present in humans. SMN2 differs from SMN1 by five nucleotides of which only one (an 840C➔T transition at exon 6–7) lies in the coding sequence and is transitionally silent. This change and a change in intron 7 cause exon 7 of the SMN2 transcript to be poorly recognized by the splicing machinery, resulting in the skipping of this exon in the majority of transcripts. This results in a frame-shift and production of a protein with a different C-terminal end, which is unstable and non-functional [ 3, 6]. Since exon 7 is sometimes included in SMN2 transcripts, some full-length SMN protein can be produced, albeit as very low levels (~10–20%) that are insufficient to prevent disease. The number of SMN2 copies varies within the general population, and is inversely associated with disease severity as having more SMN2 copies ensures that the absolute amount of SMN protein that is produced is higher. Notably, SMN2 defects in isolation do not seem to cause the disease [ 79]. Other modifiers that might play a role are NAIP, H4F5, GTF2H2 and PLS3 [ 1015]. NAIP, H4F5 and GTF2H2 are thought to be a modifiers due to their proximity to the SMN1 gene and NAIP also shows homology to apoptosis inhibitory proteins [ 12, 14, 16]. PLS3 restores the function of the neuromuscular junction, by stabilizing F-actin-dependent endocytosis [ 17].
The first therapy for SMA, Spinraza (IONIS-SMNRx, nusinersen), has recently been approved by the Food and Drug Administration (FDA) in the US [ 18] and by the European Medicines Agency (EMA) in Europe [ 19]. Clinical trials for other potential therapies are progressing. As such, the knowledge about the frequency of the disease becomes even more important. This review provides an overview of what is currently known about the prevalence, incidence and carrier frequency of SMA.

Methods

Published literature on prevalence, incidence or carrier frequency of SMA was identified through PubMed searches. Search terms were ‘spinal muscular atrophy’ OR ‘Werdnig Hoffmann’ OR ‘Kugelberg Welander’ AND ‘prevalence’ OR ‘incidence’, OR ‘carrier frequency’. No restrictions for language were used; however articles in other languages than English may be missed, due to the use of English search terms. Retrieved literature was scanned and all available articles performing a prevalence, incidence or carrier frequency study were used for this review. Additional publications were identified from references in the articles. Available literature published through 6th December 2016 was taken into account; no start date was used. For prevalence and incidence studies, all studies had determining the prevalence and/or incidence as primary goal. For carrier frequency studies also studies in which carrier frequency was determined for other purposes were included. All articles were appraised critically for accurate use of terminology and were reassigned if needed. For detailed methods on the analysis of carrier frequency differences between ethnic groups see Additional file 1.

Prevalence and incidence of SMA

To date, only a few studies have been performed to assess the prevalence and incidence of SMA. Most of these have been conducted before 1995, when the disease causing gene was identified, therefore using clinical rather than genetic diagnosis as an inclusion criterion. Generally, an estimation of the incidence of all types of SMA of around 10 in 100,000 (1 in 10,000) live births is cited [ 20, 21].

Prevalence

Prevalence is the number of living individuals with a disease at a given time. An overview of the studies examining the prevalence of SMA is provided in Table 2.
Table 2
Overview prevalence of SMA by subtype
Country
Time point
SMA
Type I
Quality and comparability
Reference
   
No of patients
Population
per 100,000
No of patients
Population
per 100,000
 
 Norway (Southern + Eastern)
01/01/1983
24
573,762
4.18
1
573,762
0.17
Only included patients below 18 years of age
Tangsrud_1988 [ 25]
 Sweden (Western)
31/12/2006
11
340,179
3.23
-
-
-
Genetic diagnosis used
Only included patients below 16 years of age
Arkblad_2009 [ 23]
 Sweden (Western)
01/01/1995
10
359,676
2.78
1
359,676
0.28
Only included patients below 16 years of age
Darin_2000 [ 24]
 Estonia
31/12/2003
-
-
-
2
1,351,069
0.15
Genetic diagnosis used
Vaidla_2006 [ 34]
 United Kingdom (Northern Ireland)
30/06/1994
22
1,573,282
1.40
-
-
-
 
Hughes_1996 [ 110]
 United Kingdom (Northern England)
01/08/2007
56
2,991,517
1.87
3
2,991,517
0.10
Genetic diagnosis used in most cases
Norwood_2009 [ 32]
 Germany (West‑Thüringen)
31/12/1987
-
-
-
3
1,778,200
0.17
 
Thieme_1993 [ 33]
 Italy (Bologna)
31/12/1989
10
152,529
6.56
-
-
-
Only included patients below 20 years of age
Merlini_1992 [ 22]
 Saudi Arabia (Northeast, Thugbah)
02/08/1989
3
22,630
13.26
1
22,630
4.42
In half of the cases parental consanguinity was observed
al Rajeh_1993 [ 29]
 China (Hongkong)
30/06/2001
25
1,335,469
1.87
2
1,335,469
0.15
Partly used genetic diagnosis
Chung_2003 [ 31]
 Canada (Toronto)
1962–1964
20.33
2,748,500
0.74
-
-
-
Average of a three-year period
Winsor_1971 [ 111]
Country
Time point
Type II
Type III
Type II + III
Quality and comparability
Reference
   
No of patients
Population
per 100,000
No of patients
Population
per 100,000
No of patients
Population
per 100,000
   
 Norway (Southern + Eastern)
01/01/1983
21
573,762
3.66
2
573,762
0.35
23
573,762
4.01
Only included patients below 18 years of age
Tangsrud_1988 [ 25]
 Sweden (Western)
01/01/1995
4
359,676
1.11
5
359,676
1.39
9
359,676
2.50
Only included patients below 16 years of age
Darin_2000 [ 24]
 United Kingdom (Northern England)
01/08/2007
17
2,991,517
0.57
36
2,991,517
1.20
53
2,991,517
1.77
Genetic diagnosis used in most cases a
Norwood_2009 [ 32]
 United Kingdom (Northeast England)
June 1971
-
-
-
-
-
-
30
2,488,810
1.21
Type II/III patients defined as: onset of disease between birth and 8 years of age, survival above 18 months of age
Pearn_1978 [ 41]
 Germany (West‑Thüringen)
31/12/1980
-
-
-
-
-
-
29
1,785,239
1.62
Type II/III patients defined as: survival above 4 years of age
Exact number of patients not mentioned b
Thieme_1994 [ 43]
 Poland (Warsaw)
31/12/1985
-
-
-
-
-
-
21
1,659,385
1.26
Exact number of patients not mentioned b
Spiegler_1990 [ 42]
 Libya (Benghazi)
31/12/1986
-
-
-
-
-
-
12
-
2.30
In half of the cases parental consanguinity was observed
Radhakrishan_1988 [ 48]
 Saudi Arabia (Northeast, Thugbah)
02/08/1989
2
22,630
8.84
-
-
-
-
-
-
In half of the cases parental consanguinity was observed
al Rajeh_1993 [ 29]
 China (Hongkong)
30/06/2001
9
1,335,469
0.67
14
1,335,469
1.05
23
1,335,469
1.72
Partly used genetic diagnosis
Chung_2003 [ 31]
Prevalence per 100,000 persons of the total population. Studies have been grouped by geographical region. Studies are based on clinical diagnosis, unless otherwise indicated. Indicated if described in article that different classification criteria than those in Table 1 were used
a) 17 patients are classified as type III on clinical and neurophysiological findings in the absence of a confirmed mutation in the SMN1 gene
b) Number of patients not described in article, calculated based on prevalence and population number
When examining all types of SMA together, in most cases a prevalence of around 1–2 per 100,000 persons is observed. In some studies a somewhat higher prevalence was observed. A study from Bologna, Italy, in 1992 calculated a prevalence of 6.56 per 100,000 persons aged less than 20 years [ 22]. Three studies in Scandinavia showed a prevalence of 4.18 per 100,000 persons aged 18 years or less, and 3.23 and 2.78 per 100,000 persons aged below 16 years [ 2325]. This could indicate regional differences in the incidence of SMA, i.e. gene pools. However, there are several other factors that may account for this observation. First of all, all studies were performed in small regions and thereby small populations were studied. For rare diseases like SMA, a small error in the detection of the number of cases can have a large impact on the estimated prevalence (sample bias). Secondly, these studies only took children into account, which is likely to influence the numbers in an upward direction. Furthermore, in the case of Sweden higher prevalence rates have also been observed in studies into other neuromuscular disorders, which could be due to a greater awareness and a good health system in Sweden, making it easier to identify patients for such a study [ 2628]. A study in Northeast Saudi Arabia also found a very high prevalence rate. Although the prevalence of SMA might be different in the Middle East when compared to Europe, in more than half of the cases parental consanguinity was observed, which could at least partially explain the high prevalence [ 29].

Prevalence by SMA subtype

Although SMA type I is expected to account for more than half of all new SMA cases [ 30], the studies that examined a SMA type I only showed a prevalence of 0.04 to 0.28 per 100,000 [ 24, 25, 3134], which is much lower than the 1–2 per 100,000 persons noted for all SMA. Due to its severity, patients with SMA type I have a short life expectancy. Therefore often no or only few patients are alive on the date of the study, which could account for this lower prevalence. Nowadays, a median life expectancy of around one year of age is estimated for type I patients [ 3537], whereas in type II 75–93% of patients survive beyond 20 years of age [ 3740] and life expectancy for type III is thought to be close to the normal population [ 20, 39].
The prevalence of both SMA type II and III together has been estimated around 1.5 per 100,000 [ 31, 32, 4143]. Of three studies that investigated type II and type III separately, two found a higher prevalence of type III compared to type II [ 24, 32]. This may be explained by the longer life expectancy of type III patients compared to type II SMA patients.

Incidence

Incidence is the number of new cases of disease in a particular time period. In the case of SMA, the genotype is present at birth; a more precise term therefore is birth prevalence. Since newborn screening is not widely performed the number of patients expressing the phenotype is used instead to estimate the incidence. An overview of the studies examining the incidence is given in Table 3.
Table 3
Overview incidence of SMA by subtype
Country
Timeframe
SMA
Type I
Quality and comparability
Reference
   
No of patients
Population
per 100,000
No of patients
Population
per 100,000
         
 Iceland
1982–1996
9
65,584
13.7
4
65,584
6.1
 
Ludvigsson_1999 [ 112]
 Sweden (Western)
1980–2006
45
531,746
8.5
19
531,746
3.6
Genetic diagnosis used
Only included patients below 16 years of age
Arkblad_2009 [ 23]
 Sweden (Western)
1979–1994
21
343,941
6.1
13
343,941
3.8
Only included patients below 16 years of age
Darin_2000 [ 24]
 Finland
1971–1985
68
952,228
7.1
53
952,228
5.6
 
Ignatius_1989 [ 51]
 Estonia
1994–2003
15
129,832
11.6
9
129,832
6.9
Genetic diagnosis used
Vaidla_2006 [ 34]
 United Kingdom (South Wales)
1973–1989
-
-
-
-
-
4.4
No details provided
MacMillan_1991 [ 113]
 United Kingdom (Northeast England)
1966–1971
-
-
-
9
231,370
3.9
Type I defined as onset of disease before 12 months of age
Pearn_1973 [ 52]
 Germany (West-Thüringen)
1974–1987
-
-
-
33
336,663
9.8
 
Thieme_1993 [ 33]
 Switzerland
1960–1969
-
-
-
62
1,100,000
5.6
Probably also contains some type II patients
Zellweger_1972 [ 55]
 Poland (Warsaw)
1976–1985
22
214,217
10.3
11
214,217
5.1
Patients described as type Ib reclassified as type II according to the description
Spiegler_1990 [ 42]
 Poland
1998–2005
304
2,963,783
10.3
209
2,963,783
7.1
Genetic diagnosis used
Jedrzejowska_2010 [ 73]
 Slovakia
 
-
-
17.8
-
-
8.1
 
Kvasnicova_1994 [ 44]
 Hungary
1973–1980
-
-
-
91
1,376,928
6.6
 
Czeizel_1989 [ 50]
 Italy (Northeast)
1960–1983
67
859,891
7.8
35
859,891
4.1
 
Mostacciuolo_1992 [ 114]
 Italy (Bologna)
1970–1989
17
150,978
11.3
8
150,978
5.3
Only included patients below 20 years of age
Merlini_1992 [ 22]
 Libya (Benghazi)
1983–1986
18
75,000
24
6
75,000
8
In half of the cases parental consanguinity was observed
Population number is an estimation
Radhakrishan_1988 [ 48]
 Reunion Island
1969–1980
-
-
-
19
24,000
79
In 13 siblings of a European community
Population number is an estimation
Pascalet-Guideon_1984 [ 115]
 Israel
1970–1975
-
-
-
4
1600
250
In an Egyptian Karaite community
Population number is an estimation
Fried_1977 [ 116]
 Canada (Toronto)
1955–1965
37
617,520
6.0
-
-
-
 
Winsor_1971 [ 111]
 USA (Ohio)
 
4
40,103
10.0
-
-
-
Genetic diagnosis used
Prior_2010 [ 101]
 USA (North Dakota)
1980–1987
-
-
-
14
94,092
14.9
 
Burd_1991 [ 53]
 Cuba
1996–2002
51
1,018,454
5.0
36
1,018,454
3.5
Partly used genetic diagnosis
Zaldivar_2002 [ 45]
Country
Timeframe
Type II
Type III
Type II + III
Quality and comparability
Reference
   
No of patients
Population
per 100,000
No of patients
Population
per 100,000
No of patients
Population
per 100,000
   
 Iceland
1982–1996
2
65,584
3.0
3
65,584
4.6
5
65,584
7.6
 
Ludvigsson_1999 [ 112]
 Sweden (Western)
1980–2006
11
531,746
2.1
15
531,746
2.8
26
531,746
4.9
Genetic diagnosis used
Only included patients below 16 years of age
Arkblad_2009 [ 23]
 Sweden (Western)
1979–1994
3
343,941
0.9 b
5
343,941
1.5
8
343,941
2.3
Only included patients below 16 years of age
Darin_2000 [ 24]
 Finland
1971–1985
-
-
-
-
-
-
15
952,228
1.6
 
Ignatius_1989 [ 51]
 United Kingdom (Northeast England)
1960–1969
-
-
-
-
-
-
15 k
365,166
4.1
 
Pearn_1978 [ 41]
 Germany (West-Thüringen)
1965–1980
-
-
-
-
-
-
42
395,646
10.6
Type II/III patients defined as: survival above 4 years of age
Thieme_1994 [ 43]
 Poland (Warsaw)
1976–1985
10
214,217
4.7
1
214,217
0.5
11
214,217
5.1
Type II defined as onset of disease before 12 months of age
Spiegler_1990 [ 42]
 Poland
1998–2005
37
2,963,783
1.2
58
2,963,783
2.0
95
2,963,783
3.2
Genetic diagnosis used
Jedrzejowska_2010 [ 73]
 Slovakia
 
-
-
3.7
-
-
5.9
-
-
9.6
 
Kvasnicova_1994 [ 44]
 Italy (Northeast)
1960–1983
19
859,891
2.2
13
859,891
1.5
32
859,891
3.7
 
Mostacciuolo_1992 [ 114]
 Italy (Bologna)
1970–1989
8
150,978
5.3 f
1
150,978
0.7
9
150,978
6.0
Only included patients below 20 years of age
Merlini_1992 [ 22]
 Libya (Benghazi)
1983–1986
-
-
-
-
-
-
12
75,000
16
In half of the cases parental consanguinity was observed
Population number is an estimation
Radhakrishan_1988 [ 48]
Incidence per 100,000 live births. Studies have been grouped by geographical region. Studies are based on clinical diagnosis, unless otherwise indicated. Indicated if described in article that different classification criteria than those in Table 1 were used
When evaluating the incidence of all types of SMA combined, on average an incidence of around 8 per 100,000 live births is found (~1 in 12,000). Some studies show a somewhat lower or higher incidence. In a study in Iceland an incidence of 13.7 per 100,000 live births was found. This is a study on an island with a relatively small population, where it might be easier to identify all patients. A study in Slovakia found a high incidence of 17.8 per 100,000, but details of the number of patients or population size were unavailable, making it difficult to interpret these findings [ 44]. In a recent study in Cuba a lower incidence of 5.0 per 100,000 was seen [ 45]. Patients were detected via an obligatory governmental registry and approximately 70% of the patients were genetically confirmed. This study also examined the ethnicity of the SMA type I patients. The majority of these patients were White (30/36), 5/36 were of mixed race and 1/36 patient was Black. Although this could be partially explained by the racial composition of the Cuban population, still relatively more White people were affected. There are several reasons that could account for this. First, there is a difference in incidence between various ethnicities. There are also reports of lower SMA carrier frequencies among Hispanics [ 46, 47]. However, it could also be the case that there are differences in the access to health care between different ethnicities. In a small study among 75,000 persons in Libya, a high incidence (24 per 100,000 live births) was found, and this may partially be explained by a high degree of consanguinity [ 48].

Incidence by subtype

In 1991, Alan Emery published a review estimating the incidence for SMA type I to be around 4–6 in 100,000 (1 in 12,500–1 in 16,667) live births [ 49], which was based on only three studies [ 5052]. We identified 17 studies, which taken together indicated an SMA I incidence of approximately 6 per 100,000. In the USA (North Dakota) in a study that pre-dated genetic testing, high incidence was observed (14.9 per 100,000); however this study was performed in a very small population, and any error in the accuracy of case identification may be associated with the high incidence. All patients studied were Caucasian and no consanguinity was observed [ 53]. In a regional study in Germany, a higher incidence of 9.8 per 100,000 was found [ 33]. In Libya, a high incidence, as found for total SMA, was not observed among type I patients (8.0 per 100,000) [ 48]. This is again based on a small population and could be due to a lack of awareness of SMA at the time the study was conducted. Furthermore, SMA type I patients might have been missed due to their short life span. In two small communities a very high incidence was observed. On Reunion Island in a European community a founder effect (loss of genetic variation that occurs when a new population is established by a very small number of individuals, which could lead to a high incidence if in one of these founders a mutation was present) was clearly seen, leading to an incidence of 79 per 100,000. In an Egyptian Karaite community in Israel, where in more than half of the affected families consanguinity was observed, an incidence of as high as 250 per 100,000 live births was found.
For type II and III, a high incidence of both types combined was observed (10.6 per 100,000) in a German study in the same region as the previously mentioned type I study that partially covered the same time period [ 33, 43]. The healthcare system in Germany may partly explain these observations. Furthermore, there might be regional differences in SMA incidence. The authors suggest that SMA might be more prevalent in central and Eastern Europe than in Western Europe. For type II and type III SMA the highest occurrence was observed in Libya (16 per 100,000) [ 48].
A study not added in Table 3 is a study from Kurland et al. in Rochester, USA, studying the period 1945–1954. This study found only one SMA type I patient and the calculations used the total population size instead of the number of live births to calculate the incidence. Furthermore, this total population consisted of only 30,000 persons [ 54].
The epidemiologic burden of SMA is not equally divided over the subtypes. In 2004 Ogino et al. reviewed several studies and calculated incidence rates of 5.83 per 100,000 live births for SMA type I, 2.66 per 100,000 live births for type II and 1.20 per 100,000 live births for type III. This implied that SMA type I, II and III constituted 60%, 27% and 12% of all SMA cases, respectively [ 30]. This overview included the study of Radhakrishan et al. in Libya, in which for half of the families parental consanguinity was observed [ 48]. In our analysis, we calculated the percentages in two ways yielding nearly identical results. First by only taking studies into account in which all types of SMA were studied separately, as this makes a direct comparison possible; and, secondly by taking all studies presented into account. In both cases this resulted in incidence rates of around 5.5, 1.9 and 1.7 per 100,000 for type I, II and III, respectively. This yields a percentage of around 60% for the incidence of SMA type I; with the remaining 40% of the cases equally divided between type II and type III. This indicates that SMA I indeed makes up the largest proportion of the total SMA.

Considerations for comparing studies

To date, there are few studies of the prevalence and/or incidence of SMA, with a small number of these being recent. Most of the studies have been carried out in Europe. Furthermore, four of the ten studies done outside of Europe were performed in the countries with high consanguinity or small communities, thereby they are not considered to be representative of the overall SMA prevalence and incidence. No worldwide studies have been published to date.
A number of limitations should be taken into account when estimating prevalence/ incidence of SMA and comparing the presented studies. Most studies have been performed before 1995 when the genetic cause for SMA, deletion of the SMN1 gene, was identified [ 3], where after genetic diagnosis was implemented. Therefore, most studies rely on the less accurate clinical diagnosis of SMA. This increases the chance of misdiagnosis of diseases with clinical features similar to SMA. Another difficulty comparing studies is that the classification of SMA has slightly changed over the years and it is not always clear which classification system has been used. For example, in the studies of John Pearn in Northeast England patients were defined as SMA type I if they had an onset of symptoms before the age of 12 months, so this might also include some early diagnosed SMA type II patients [ 41, 52]. Chronic SMA was classified as patients living beyond 18 months old. However, in the study in West-Thüringen, Germany patients had to survive till at least four years of age to be classified as chronic SMA [ 43]. This is further exemplified by the study of Spiegler et al. in Warsaw, Poland. In this study type Ib patients are mentioned, and are defined as patients diagnosed at birth or in the first months of life and living up to 30 years, whereas type II SMA was described as having an onset at the age of one year onwards [ 42]. In the study of Zellweger et al. in Switzerland it is not clearly specified which definitions were used, but it is conceivable that some type II patients are included in the numbers of type I patients [ 55]. Currently, the classification of the main subtypes: I, II and III (and sometimes IV) as described in Table 1 is used.
Another factor that should be taken into account is that the studies have been performed in different time periods. The natural history of SMA has changed over the years as the standards of care and associated outcomes have largely improved in the recent years. For example for type I comparison of studies showed the mean age of death increased from 8.8–10 months in studies performed before 1995 to 10.4 months up to 4 years in studies performed after 2000 [ 35, 36]. This is partly due to the availability of assisted ventilation (non-invasive or through tracheostomy) and of tube feeding through a gastrostomy [ 36].
Lastly, most of the studies have been performed in small geographical areas, thereby including a relatively small study population. One or two patients more or less in a small patient population will have a strong effect on the calculated prevalence or incidence. All these factors make a comparison between the studies and the interpretation of the findings difficult.
In conclusion, few prevalence and incidence studies have been performed for SMA, of which most are based on clinical diagnosis and are performed in European countries or regions, using small study populations. In addition to prevalence and incidence studies, carrier frequencies can provided useful additional information about, for example, ethnic subpopulations.

Carrier frequency in SMA

Since SMA is a recessive disease, there are also unaffected, heterozygous carriers of the disease. Carriers fall into four main groups of genotypes (Fig. 1). The most common one is the ‘1 + 0’ genotype (one normal, functional allele and a SMN1 deleted, disease allele). A much less common category is the ‘2 + 0’ genotype with two functional genes on one chromosome and none on the other. Furthermore, there are also ‘1 + 1 D’ and ‘2 + 1 D’ genotypes, which have one or two functional genes on one chromosome and a non-functional gene due to either a point mutation or a microdeletion on the other. These last two genotypes are very rare [ 56, 57]. Four or even more copies of the SMN1 gene have also been found, indicating a ‘2 + 2’ or possibly a ‘3 + 1’ genotype. This suggests ‘3 + 0’ or ‘3 + 1 D’ carrier genotypes might also be possible, however these will be even rarer.
No signs of disease have been associated with being a carrier for SMA. However, some studies suggest abnormal SMN1 copy numbers (either deletions or duplications) may increase the risk and severity of sporadic amyotrophic lateral sclerosis (ALS), although other studies have been unable to confirm this association (for a review see Butchbach et al., 2016 [ 58]). Furthermore, it was suggested that in the rare disorder progressive muscular atrophy (PMA) SMN1 duplications might be associated with a more severe clinical phenotype [ 59].
After the discovery of mutations in SMN1 as the cause of SMA, several studies into the carrier status of SMA have been performed. In contrast to the prevalence/ incidence studies, most studies have been performed outside of Europe. Some of these are population screening programmes, whereas others are large samples of the general population [ 46, 6081]. There are also studies where small population samples were analysed or the carrier frequency was estimated from healthy controls screened for SMN1 for other purposes [ 8, 30, 8299]. As mentioned before, frequencies estimated from a small population sample are less accurate. An overview of all studies is given in Additional file 2.

Subpopulation differences

Some of the studies have examined differences between ethnic groups within their study population [ 46, 6265, 77, 80]. The main finding was that copy numbers were significantly higher in Black (Sub-Saharan African ancestry) people. This was seen in African Americans [ 46, 62, 77], as well as in Black Africans [ 66] and would indicate a higher proportion of 2-copy (duplication) alleles, thereby suggesting a higher number of ‘2 + 0’ carriers. This could account for a lower detection rate (around 70% for Black people versus 90–95% for other ethnicities), leading to a high number of false negatives. The study in Africa found a significantly lower carrier frequency compared to Eurasians [ 66]. Lower carrier frequencies were also seen in a study comparing Black and White people in South Africa and a study among samples of the 1000 genome project [ 65, 80]. However, these studies could not detect the ‘2 + 0’ carriers, which could reduce the observed differences. Some studies also found lower carrier frequencies in Hispanics [ 46, 77], but this was not seen in other studies [ 62, 69, 80]. Lastly, Luo et al. identified a specific haplotype, present in Ashkenazi Jews and Asians detectable by microsatellite analysis, that could distinguish duplication alleles (present in ‘2 + 0’ carriers) from normal ‘1 + 1’ genotypes [ 77].
We carried out an analysis of differences between ethnic groups and studies. Fig. 2 shows a comparison of all studies described in Additional file 2 (ethnicities are indicated). The grey area indicates the 95% confidence interval based on the average carrier frequency of all studies combined (0.019). 1 Most studies fall within this area, indicating no large differences in carrier frequency. Two populations (a Muslim Arab village in Israel and a specific group of Hutterites in South Dakota, USA) showed a particularly high carrier frequency. However, these are isolated populations with a high degree of inbreeding [ 81, 89]. Also in an Iranian population a higher carrier frequency was seen (1 in 20). However this is based on one study with a small sample size, furthermore, in Iran, consanguineous marriages are common [ 91]. Combined estimates of carrier frequencies for ethnic groups were calculated (large symbols in Fig. 2 and Table 4).
Table 4
Carrier frequencies for SMA per ethnicity
Population
Number of identified carriers
Number of study participants
Carrier frequency
95% CI
Arab a
152
9058
0.017
0.014–0.019
Asian
2492
119,718
0.021
0.020–0.022
Asian Indian
20
1465
0.014
0.008–0.020
Black (Sub-Saharan ancestry)
80
8012
0.010
0.008–0.012
Caucasian
680
31,549
0.022
0.020–0.023
Hispanic
127
9649
0.013
0.011–0.015
Jewish
1059
59,196
0.018
0.017–0.019
Median and 95% posterior intervals of SMA carrier frequencies, based on studies presented in Additional file 2. Only ethnicities studied in more than one study are included
CI confidence interval
a) The isolated Muslim Israeli Arab village [ 59] has been omitted
The results show that the highest frequencies are found in Caucasian and Asian populations (around 1 in 50) and the lowest in Black (1 in 100) and Hispanics (1 in 76) populations. However, it is important to note that genetically Hispanics are a very mixed group, making generalizations difficult. This is also demonstrated by the fact that some studies among Hispanics found much higher frequencies [ 69, 80], while others found that the frequencies were lower [ 46].

SMN1 copy number differences between populations

In 2014, MacDonald et al. have performed a meta-analysis comparing the SMA carrier frequency among different ethnicities. In their analysis they included 14 studies where ethnicities were described and results were broken down by SMA copy number [ 47]. They took the different carrier genotypes described above into account and determined the carrier rates in the ethnic groups. Furthermore, they calculated the reduced risk of being a carrier if a 2- or 3-copy result was found. This again showed a substantially higher carrier risk with a 2-copy test result for Black people. In addition a very high carrier risk and 2-copy risk in Iranians was found. However, this is based on one study only [ 91].
The Additional file 3 shows all studies that examined at the SMN1 copy number status. None of the studies among Arabian populations performed this analysis, therefore this group has not been included in the table. SMN1 allele frequencies were determined for each group (Table 5) using copy numbers (for methods and calculations see Additional file 1).
Table 5
SMN1 allele frequencies per ethnicity
 
Frequency by number of SMN1 copies on a single allele
 
0 Copies
1 Copy
2 Copies
Ethnicity a
Portion
95% CI
Portion
95% CI
Portion
95% CI
Asian
0.010
0.010–0.011
0.949
0.948–0.950
0.040
0.039–0.041
Asian Indian b
0.010
0.006–0.015
0.908
0.894–0.921
0.082
0.070–0.095
Black (Sub-Saharan ancestry)
0.007
0.005–0.009
0.717
0.708–0.725
0.276
0.268–0.285
Caucasian
0.011
0.010–0.012
0.954
0.952–0.955
0.035
0.034–0.037
Hispanic
0.007
0.006–0.008
0.915
0.911–0.919
0.078
0.074–0.082
Jewish
0.010
0.009–0.011
0.934
0.931–0.936
0.057
0.054–0.059
Median and 95% posterior intervals of copy number allele frequency, based on studies presented in Additional file 3
CI confidence interval
a) Same ethnicities as in Table 4 are included
b) Only consists of one study
The copy number 0 (carriers) is lower in Blacks and Hispanics. Whilst there is not a great difference in the two copy number frequencies between other ethnicities, this is much higher in the Black population. As is seen in Table 6, this indicates a higher number of hidden carriers (‘2 + 0’ genotype), thereby decreasing the sensitivity of most carrier tests used, which only measure the copy numbers. Therefore, it is important to take the ethnicity into account when performing population screening or genetic counselling and consider a different method to reduce the chance of false negative results. In Table 6 also disease frequencies are estimated by combining the copy number results with an estimated small mutation (1 D) frequency of 4% [ 4, 5] and an estimated de novo mutation frequency of 2% [ 100]. Thereafter, the incidences rates were estimated using these frequencies (Table 7).
Table 6
Carrier, SMN1 copy number 2 carrier and disease frequencies per ethnicity
 
Adjusted carrier and disease frequencies
 
1 SMN1 copy carriers
2 S MN1 copies carriers
Disease Frequency
Ethnicity
Frequency
95% CI
Frequency
95% CI
Frequency
95% CI
Asian
0.022
0.021–0.023
0.0014
0.0012–0.0015
1.3E-04
1.2E-04-1.4E-04
Asian Indian a
0.020
0.012–0.030
0.0021
0.0014–0.0030
1.0E-04
4.0E-05-2.4E-04
Black (Sub-Saharan ancestry)
0.014
0.011–0.018
0.0042
0.0034–0.0052
5.3E-05
3.4E-05-8.1E-05
Caucasian
0.022
0.021–0.024
0.0013
0.0011–0.0014
1.3E-04
1.1E-04-1.5E-04
Hispanic
0.014
0.011–0.017
0.0015
0.0013–0.0018
5.0E-05
3.5E-05-7.0E-05
Jewish
0.020
0.018–0.022
0.0016
0.0014–0.0018
1.0E-04
8.3E-05-1.2E-04
Median and 95% posterior intervals of carrier, copy number 2 carriers and disease frequencies. Frequencies calculated based on allele frequencies, small mutation and de novo mutation frequencies (calculations described in Additional File 1)
CI confidence interval
a) Based on results of only one study
Table 7
Estimated incidence from carrier frequency per ethnicity
Ethnicity
Incidence estimate (1 in)
95% CI
Asian
8009
7382–8684
Asian Indian a
9655
4227–25,057
Black (Sub-Saharan ancestry)
18,808
12,331–29,559
Caucasian
7829
6750–9093
Hispanic
20,134
14,218–28,894
Jewish
10,000
8343–12,038
Median and 95% posterior intervals of incidence estimated from carrier and disease frequencies as calculated in Table 6
a) Based on results of only one study
The incorporation of estimated carrier risks for people with a 2 copy number result, generates only a slightly lower incidence (~1 in 54) for the Black populations compared to most other populations (~1 in 45), due to presence of a much higher number of multiple SMN1 copy number alleles in this population. The estimation of the combined carrier frequency in Hispanics is lower than in other populations (1 in 65), as was also seen in the previous estimations. It must be noted however that here only a subset of studies is used compared to the comparison of all studies (Fig. 2 and Table 4), which can also contribute to differences in estimations.
The combined results lead to the highest incidence estimations of around 1 in 8000 in Asians and Caucasians, whilst lower incidence of around 1 in 20,000 are estimated in the Black and Hispanic populations.
In Caucasians, the incidence rate estimated from carrier frequencies is higher than the observed incidence rates in studies (Table 3, ~1 in 11,000). Carrier frequency estimates are solely based on genetic studies, whilst most incidence studies were based on clinical diagnosis and are mostly much older. However, carrier frequency incidence estimates could be an overestimation of the true incidence due to reduced penetrance. Here a penetrance of 100% is assumed. If the penetrance is decreased by 10% (i.e. penetrance of 90%) the incidence would also decrease by 10%. It might be that some cases of SMA are so severe that they lead to premature death in utero. SMN2 is absent in 10–15% of the general population [ 101], and deletions of both SMN1 and SMN2 are embryonically lethal. Furthermore increased awareness could lead to more genetic counselling of couples at risk, certainly in couples who have previous children or family members with SMA. In addition, sporadic cases of unaffected individuals without functional SMN1 cases have been described [ 96, 102109]. This might be due to high copy numbers of SMN2, since, as mentioned before, SMN2 copy number influences the severity of the disease [ 79]. Therefore, it is important to take SMN2 copy number into account when performing newborn screening.

Conclusions

SMA is a severe, heterogeneous, neuromuscular disorder. The few available prevalence and incidence studies mainly predate genetic testing and were performed in small geographical areas, mainly in Europe. This highlights the need for larger, more generalizable prevalence studies.
Recently, carrier frequency of SMA in healthy populations has been studied quite extensively, indicating differences between ethnicities not only in carrier frequency, but also in copy number status. In some groups this decreases the sensitivity of commonly used carrier testing methods. This emphasizes the need to use methods that enable to detect carriers having two SMN1 copies on one chromosome and none on the other.
Good epidemiological data is needed to gain insight into health care needs and for research studies and clinical trials. This is especially important in rare diseases where clinical trials require a careful planning. Furthermore, newborn screening will become increasingly important, especially now a drug has been approved and other new therapies are in advanced clinical trial stages. The introduction of new therapies is also likely to impact on the prevalence of SMA and as such may have significant resource implications for health care planning.

Acknowledgments

The Institute of Genetic Medicine in Newcastle is part of the MRC Centre for Neuromuscular Diseases and the TREAT-NMD Alliance. AR receives funding from SMA Support UK. HL is a principal investigator in the MRC Centre for Neuromuscular Diseases.

Funding

The writing of this manuscript was funded by Biogen MA Inc.

Availability of data and materials

The datasets supporting the conclusions of this article are included within the article and its Additional files 1, 2 and 3.

Authors’ contributions

IV performed the literature review, drafted and revised the manuscript. AR, AAR, SC, CJ and SFC reviewed the manuscript and provided comments and suggestions. IW performed the bioinformatical analysis. SC and CJ reviewed the manuscript and reviewed for English language. HL reviewed the manuscript and supervised the process. All authors read and approved the final manuscript.

Competing interests

IV, AR, IW, AAR, SC and HL declare that they have no competing interests. CJ is employed by and stakeholder of Biogen MA Inc. SFC is a consultant to Biogen MA Inc.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Footnotes
1
Two studies in studies in populations with a high inbreed rate (a Muslim Arab village in Israel and a Hutterite community in South Dakota, USA) are not included in the average.
 
Zusatzmaterial
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

Orphanet Journal of Rare Diseases 1/2017 Zur Ausgabe